Navigation Links
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Date:9/16/2009

nts made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
2. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
4. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
5. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
6. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
7. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
8. AEterna Zentaris Receives US$10 Million from Institutional Investors
9. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
10. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 /PRNewswire/ ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on Wednesday, ... be accessed via a live webcast on the United Therapeutics ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... the developing world could reduce the environmental impact of ... writing today in the Inderscience publication, International Journal of ... the developing world are encouraged to compost our garden ... bin and not all of us are willing or ...
... DENVER, Sept. 18 The future of health ... integrated into practice and,health policy. But putting research ... slow the pace of cutting-edge care. Kaiser,Permanente Colorado ... aimed at getting research into practice and policy ...
... Sept. 18 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... and Chief Financial Officer, will present at the 2007,UBS ... Grand Hyatt on,Tuesday, September 25, 2007 at 10:00 a.m. ... of the presentation by,visiting the "Events Calendar" page under ...
Cached Biology Technology:Landfill Mining 2Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research 2Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... through which it can protect itself against newly-developing cancer ... in our organs every day. Once tumours have developed, ... from the immune system. Scientists from the research group ... (HZI) in Braunschweig have now succeeded to reveal a ...
... in the lungs of people who smoke may offer a ... emphysema before the disease damages and eventually destroys areas of ... The study found that smokers who have very subtle signs ... different blood flow patterns in their lungs compared to non-smokers ...
... April 6, 2010 Chronix Biomedical today announced publication ... serum DNA blood tests to predict clinical status and ... sclerosis (MS). Chronix Biomedical uses proprietary technology to ... that is released into the bloodstream by damaged and ...
Cached Biology News:The immune system's guard against cancer 2The immune system's guard against cancer 3New test could identify smokers at risk of emphysema 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 3
... product contains 5 ml Dynabeads® ... the monoclonal BerEP4 against the ... cell adhesion molecule). Also available ... 2 x 10e7 MNC in ...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
Biology Products: